Literature DB >> 19189182

Passive protection assay of monoclonal antibodies against dengue virus in suckling mice.

Zongtao Chen1, Li-Mei Liu, Na Gao, Xiao-Feng Xu, Jun-Lei Zhang, Jia-Li Wang, Jing An.   

Abstract

Dengue fever and dengue hemorrhagic fever/dengue shock syndrome are highly infectious diseases caused by dengue virus (DV). Specific monoclonal antibodies (mAbs) against DV are vital for diagnosis, pathological studies, and passive immune therapy. In this study, purified DV serotype 2 (DV2) was used as antigen and BALB/c mice were immunized to induce specific antibodies. We established five hybridoma cell lines, called 78#, 1E7, 7F7, 8F12, and 8H1, respectively, and evaluated them by enzyme-linked immunosorbent assay, indirect immunofluorescence assay, Western blot, plaque reduction neutralization test, and suckling mice protection assay. Lines 78#, 1E7, 7F7, and 8F12 showed a neutralizing effect, and lines 78#, 1E7, 8F12, and 8H1 recognized envelope glycoprotein of DV2. Among them, lines 78# and 8F12 had stronger neutralizing ability in vitro and could protect some suckling mice from virus challenge. Our results demonstrate that immunization with purified virion is efficient for the production of specific neutralizing mAbs against DV2, and these mAbs could be useful tools for studying or treating DV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19189182     DOI: 10.1007/s00284-009-9356-4

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  19 in total

1.  Mutational evidence for an internal fusion peptide in flavivirus envelope protein E.

Authors:  S L Allison; J Schalich; K Stiasny; C W Mandl; F X Heinz
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Live attenuated tetravalent dengue vaccine.

Authors:  N Bhamarapravati; Y Sutee
Journal:  Vaccine       Date:  2000-05-26       Impact factor: 3.641

3.  Characterization of dengue-2 virus binding to surfaces of mammalian and insect cells.

Authors:  Butsaya K Thaisomboonsuk; Edward T Clayson; Somsak Pantuwatana; David W Vaughn; Timothy P Endy
Journal:  Am J Trop Med Hyg       Date:  2005-04       Impact factor: 2.345

Review 4.  Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections.

Authors:  Søren Bregenholt; Allan Jensen; Johan Lantto; Sara Hyldig; John S Haurum
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

5.  Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys.

Authors:  R Putnak; D A Barvir; J M Burrous; D R Dubois; V M D'Andrea; C H Hoke; J C Sadoff; K H Eckels
Journal:  J Infect Dis       Date:  1996-12       Impact factor: 5.226

6.  Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice.

Authors:  B A Fonseca; S Pincus; R E Shope; E Paoletti; P W Mason
Journal:  Vaccine       Date:  1994       Impact factor: 3.641

7.  Production and characterization of monoclonal antibody specific to recombinant dengue multi-epitope protein.

Authors:  Ajay Vinayak Abhyankar; Rakesh Bhargava; Asha Mukul Jana; Ajay Kumar Sahni; P V Lakshmana Rao
Journal:  Hybridoma (Larchmt)       Date:  2008-06

Review 8.  Antigenic structure of flavivirus proteins.

Authors:  John T Roehrig
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

Review 9.  Serologic diagnosis of West Nile virus infection.

Authors:  Pei-Yong Shi; Susan J Wong
Journal:  Expert Rev Mol Diagn       Date:  2003-11       Impact factor: 5.225

10.  Structural basis of West Nile virus neutralization by a therapeutic antibody.

Authors:  Grant E Nybakken; Theodore Oliphant; Syd Johnson; Stephen Burke; Michael S Diamond; Daved H Fremont
Journal:  Nature       Date:  2005-09-29       Impact factor: 49.962

View more
  2 in total

1.  Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Michael Engle; James D Brien; Kimberly A Dowd; Katherine L Williams; Syd Johnson; Rebeca Rico-Hesse; Eva Harris; Theodore C Pierson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.